240 related articles for article (PubMed ID: 24447935)
1. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
[TBL] [Abstract][Full Text] [Related]
2. Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.
Ko JC; Wang TJ; Chang PY; Syu JJ; Chen JC; Chen CY; Jian YT; Jian YJ; Zheng HY; Chen WC; Lin YW
Biochem Pharmacol; 2015 Oct; 97(3):331-40. PubMed ID: 26212550
[TBL] [Abstract][Full Text] [Related]
3. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Chen JC; Wang TJ; Zheng HY; Chen WC; Chang PY; Lin YW
Biochem Pharmacol; 2016 Apr; 105():91-100. PubMed ID: 26921637
[TBL] [Abstract][Full Text] [Related]
4. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
6. Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression.
Ko JC; Zheng HY; Chen WC; Peng YS; Wu CH; Wei CL; Chen JC; Lin YW
Biochem Pharmacol; 2016 Dec; 122():90-98. PubMed ID: 27666600
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Chen CY; Jian YT; Huang YJ; Wo TY; Jian YJ; Chang PY; Wang TJ; Lin YW
Biochem Biophys Res Commun; 2015 Jan; 456(1):506-12. PubMed ID: 25490383
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells.
Ko JC; Chen JC; Hsieh JM; Tseng PY; Chiang CS; Liu LL; Chien CC; Huang IH; Chang QZ; Mu BC; Lin YW
Biochem Pharmacol; 2022 Oct; 204():115207. PubMed ID: 35961402
[TBL] [Abstract][Full Text] [Related]
11. Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Chen JC; Wu CH; Peng YS; Chen WC; Zheng HY; Jian YJ; Wei CL; Cheng YT; Lin YW
Exp Cell Res; 2017 Aug; 357(1):59-66. PubMed ID: 28454878
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.
Weng SH; Tsai MS; Chiu YF; Kuo YH; Chen HJ; Lin YW
Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):298-306. PubMed ID: 21973306
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
15. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Ko JC; Wang LH; Jhan JY; Ciou SC; Hong JH; Lin ST; Lin YW
Lung Cancer; 2009 Sep; 65(3):290-8. PubMed ID: 19157634
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
17. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Shen H; Yuan Y; Sun J; Gao W; Shu YQ
Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
